Neuroimmunology Clinic and Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
University of Alabama School of Public Health, Birmingham, Alabama, USA.
Ann Clin Transl Neurol. 2023 Apr;10(4):664-667. doi: 10.1002/acn3.51750. Epub 2023 Feb 28.
The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.
髓鞘少突胶质细胞糖蛋白抗体病(MOGAD)患者的死亡率目前尚不清楚。本研究旨在评估大型 MOGAD 患者队列的死亡率。由于我们队列中的患者均未死亡,因此我们估计队列的粗死亡率 95%置信区间上限为 2.1%。这些数据表明,MOGAD 患者的死亡率低于其他神经炎性疾病报告的死亡率,与美国普通人群的年龄调整死亡率相当。需要进一步的研究来证实这一观察结果。